Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.40
HAE's Cash to Debt is ranked higher than
57% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.74 vs. HAE: 0.40 )
HAE' s 10-Year Cash to Debt Range
Min: 0.09   Max: 60.69
Current: 0.4

0.09
60.69
Equity to Asset 0.56
HAE's Equity to Asset is ranked higher than
65% of the 285 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.63 vs. HAE: 0.56 )
HAE' s 10-Year Equity to Asset Range
Min: 0.52   Max: 0.84
Current: 0.56

0.52
0.84
F-Score: 6
Z-Score: 2.99
M-Score: -2.79
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 6.33
HAE's Operating margin (%) is ranked higher than
70% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.44 vs. HAE: 6.33 )
HAE' s 10-Year Operating margin (%) Range
Min: 4.57   Max: 23.59
Current: 6.33

4.57
23.59
Net-margin (%) 4.35
HAE's Net-margin (%) is ranked higher than
70% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.65 vs. HAE: 4.35 )
HAE' s 10-Year Net-margin (%) Range
Min: -8.68   Max: 16.46
Current: 4.35

-8.68
16.46
ROE (%) 5.04
HAE's ROE (%) is ranked higher than
68% of the 283 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.68 vs. HAE: 5.04 )
HAE' s 10-Year ROE (%) Range
Min: -12.74   Max: 17.39
Current: 5.04

-12.74
17.39
ROA (%) 2.65
HAE's ROA (%) is ranked higher than
70% of the 290 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.24 vs. HAE: 2.65 )
HAE' s 10-Year ROA (%) Range
Min: -7.37   Max: 12.66
Current: 2.65

-7.37
12.66
ROC (Joel Greenblatt) (%) 10.90
HAE's ROC (Joel Greenblatt) (%) is ranked higher than
70% of the 288 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.38 vs. HAE: 10.90 )
HAE' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 7.85   Max: 54.69
Current: 10.9

7.85
54.69
Revenue Growth (%) 11.30
HAE's Revenue Growth (%) is ranked higher than
83% of the 248 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. HAE: 11.30 )
HAE' s 10-Year Revenue Growth (%) Range
Min: -1.5   Max: 15
Current: 11.3

-1.5
15
EBITDA Growth (%) -1.00
HAE's EBITDA Growth (%) is ranked higher than
65% of the 210 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.40 vs. HAE: -1.00 )
HAE' s 10-Year EBITDA Growth (%) Range
Min: -56.2   Max: 106.5
Current: -1

-56.2
106.5
EPS Growth (%) -12.90
HAE's EPS Growth (%) is ranked higher than
61% of the 220 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.90 vs. HAE: -12.90 )
HAE' s 10-Year EPS Growth (%) Range
Min: -74.3   Max: 141
Current: -12.9

-74.3
141
» HAE's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

HAE Guru Trades in Q1 2013

Paul Tudor Jones 12,200 sh (+58.44%)
Ken Fisher 166,920 sh (+26.97%)
Meridian Funds 390,500 sh (+10.12%)
Pioneer Investments 137,480 sh (+4.4%)
Columbia Wanger 1,170,000 sh (unchged)
Jean-Marie Eveillard 8,000 sh (unchged)
Steven Cohen 18,207 sh (-17.62%)
Third Avenue Management 58,000 sh (-25.64%)
» More
Q2 2013

HAE Guru Trades in Q2 2013

Jim Simons 233,900 sh (New)
Chuck Royce 328,000 sh (New)
Meridian Funds 439,500 sh (+12.55%)
Jean-Marie Eveillard 9,000 sh (+12.5%)
Ken Fisher 169,245 sh (+1.39%)
Columbia Wanger 1,170,000 sh (unchged)
Pioneer Investments Sold Out
Steven Cohen 14,644 sh (-19.57%)
Paul Tudor Jones 9,800 sh (-19.67%)
Third Avenue Management 42,000 sh (-27.59%)
» More
Q3 2013

HAE Guru Trades in Q3 2013

Jim Simons 237,500 sh (+1.54%)
Ken Fisher 169,245 sh (unchged)
Jean-Marie Eveillard 9,000 sh (unchged)
Third Avenue Management 42,000 sh (unchged)
Steven Cohen Sold Out
Paul Tudor Jones 8,700 sh (-11.22%)
Chuck Royce 224,100 sh (-31.68%)
Columbia Wanger 456,120 sh (-61.02%)
» More
Q4 2013

HAE Guru Trades in Q4 2013

Steven Cohen 19,006 sh (New)
James Barrow 958,209 sh (New)
Jean-Marie Eveillard 10,000 sh (+11.11%)
Columbia Wanger Sold Out
Chuck Royce Sold Out
Third Avenue Management Sold Out
Ken Fisher 147,995 sh (-12.56%)
Paul Tudor Jones 5,900 sh (-32.18%)
Jim Simons 26,100 sh (-89.01%)
» More
» Details

Insider Trades

Latest Guru Trades with HAE

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
James Barrow 2013-12-31 New Buy0.06%$38.87 - $43.83 $ 33.21-19%958209
Meridian Funds 2012-12-31 Add 100%0.29%$38.92 - $41.38 $ 33.21-18%354600
Jean-Marie Eveillard 2012-12-31 Add 100%$38.92 - $41.38 $ 33.21-18%8000
Meridian Funds 2012-09-30 Add 21.86%0.09%$68.61 - $81.4 $ 33.21-55%177300
Meridian Funds 2012-06-30 New Buy0.36%$66.79 - $73.87 $ 33.21-52%145500
Joel Greenblatt 2012-03-31 Sold Out 0.12%$61.85 - $70.45 $ 33.21-47%0
Joel Greenblatt 2011-09-30 Add 77.59%0.05%$56.03 - $69.18 $ 33.21-47%13062
George Soros 2011-09-30 Sold Out 0.0046%$56.03 - $69.18 $ 33.21-47%0
Joel Greenblatt 2011-06-30 Reduce -21.71%0.04%$62.42 - $70.2 $ 33.21-50%7355
Joel Greenblatt 2011-03-31 New Buy0.18%$58.18 - $65.06 $ 33.21-46%9395
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Haemonetics Corporation

Meridian Funds Comments on Haemonetics - Aug 28, 2013

Haemonetics (HAE) is the market leader in blood management products for collection centers and hospitals. The company's equipment and related consumables allow collection centers to separate blood into the components of plasma, red cells and white cells. Hospital-based products include blood diagnostics, devices to salvage patient blood during surgery and software to manage blood supply. Earnings temporarily declined due to two product quality issues that management of Haemonetics has stated have been remedied. In our opinion, earnings growth may be expected to accelerate in the next few years as Haemonetics rolls out its automated whole blood collection solution to collection centers. Relative to the existing manual process, the company's automated solution speeds up the collection process and reduces discard rates. Cost and efficiency gains become more important to collection centers as hospitals better manage their blood supply. We believe the company is a compelling value at 12x our $3.50 estimate of earnings power.

From Meridian Funds' June 30, 2013 commentary.


Check out Meridian Funds latest stock trades

Top Ranked Articles about Haemonetics Corporation

Meridian Funds Comments on Haemonetics
Haemonetics (HAE) is the market leader in blood management products for collection centers and hospitals. The company's equipment and related consumables allow collection centers to separate blood into the components of plasma, red cells and white cells. Hospital-based products include blood diagnostics, devices to salvage patient blood during surgery and software to manage blood supply. Earnings temporarily declined due to two product quality issues that management of Haemonetics has stated have been remedied. In our opinion, earnings growth may be expected to accelerate in the next few years as Haemonetics rolls out its automated whole blood collection solution to collection centers. Relative to the existing manual process, the company's automated solution speeds up the collection process and reduces discard rates. Cost and efficiency gains become more important to collection centers as hospitals better manage their blood supply. We believe the company is a compelling value at 12x our $3.50 estimate of earnings power. Read more...
Weeky CFO Sells Highlight: ADBE, HAE, WAGE, OVTI, ICPT
According to GuruFocus Insider Data, the largest CFO sells during the past week were: Adobe Systems Inc., Haemonetics Corporation, WageWorks Inc., OmniVision Technologies Inc. and Intercept Pharmaceuticals Inc. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 46.00
HAE's P/E(ttm) is ranked lower than
63% of the 199 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.10 vs. HAE: 46.00 )
HAE' s 10-Year P/E(ttm) Range
Min: 16.01   Max: 110.8
Current: 46

16.01
110.8
P/B 2.10
HAE's P/B is ranked higher than
78% of the 278 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.77 vs. HAE: 2.10 )
HAE' s 10-Year P/B Range
Min: 1.8   Max: 3.97
Current: 2.1

1.8
3.97
P/S 1.80
HAE's P/S is ranked higher than
69% of the 292 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.60 vs. HAE: 1.80 )
HAE' s 10-Year P/S Range
Min: 1.24   Max: 3.59
Current: 1.8

1.24
3.59
PFCF 29.20
HAE's PFCF is ranked higher than
57% of the 164 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.00 vs. HAE: 29.20 )
HAE' s 10-Year PFCF Range
Min: 9.74   Max: 130.83
Current: 29.2

9.74
130.83
EV-to-EBIT 37.00
HAE's EV-to-EBIT is ranked lower than
66% of the 247 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 18.32 vs. HAE: 37.00 )
HAE' s 10-Year EV-to-EBIT Range
Min: 9.9   Max: 71.9
Current: 37

9.9
71.9
PEG 38.30
HAE's PEG is ranked lower than
71% of the 134 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.13 vs. HAE: 38.30 )
HAE' s 10-Year PEG Range
Min: 0.69   Max: 38.3
Current: 38.3

0.69
38.3
Shiller P/E 28.60
HAE's Shiller P/E is ranked higher than
58% of the 127 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 25.28 vs. HAE: 28.60 )
HAE' s 10-Year Shiller P/E Range
Min: 21.83   Max: 49.48
Current: 28.6

21.83
49.48

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 8.00
HAE's Price/Tangible Book is ranked lower than
70% of the 232 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. HAE: 8.00 )
HAE' s 10-Year Price/Tangible Book Range
Min: 1.7   Max: 13.83
Current: 8

1.7
13.83
Price/DCF (Projected) 1.30
HAE's Price/DCF (Projected) is ranked higher than
72% of the 147 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.40 vs. HAE: 1.30 )
HAE' s 10-Year Price/DCF (Projected) Range
Min: 1.09   Max: 2.56
Current: 1.3

1.09
2.56
Price/Median PS Value 0.70
HAE's Price/Median PS Value is ranked higher than
84% of the 268 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.10 vs. HAE: 0.70 )
HAE' s 10-Year Price/Median PS Value Range
Min: 0.55   Max: 1.4
Current: 0.7

0.55
1.4
Price/Graham Number 4.00
HAE's Price/Graham Number is ranked lower than
71% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.20 vs. HAE: 4.00 )
HAE' s 10-Year Price/Graham Number Range
Min: 1.08   Max: 7.86
Current: 4

1.08
7.86
Earnings Yield (Greenblatt) 2.70
HAE's Earnings Yield (Greenblatt) is ranked lower than
59% of the 226 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.40 vs. HAE: 2.70 )
HAE' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.4   Max: 10.1
Current: 2.7

1.4
10.1
Forward Rate of Return (Yacktman) 1.29
HAE's Forward Rate of Return (Yacktman) is ranked higher than
73% of the 217 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.90 vs. HAE: 1.29 )
HAE' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 1   Max: 29
Current: 1.29

1
29

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:HAZ.Germany
Haemonetics Corporation is a healthcare company that provides blood management solutions to its customers. Its portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood supply chain, helps improve clinical outcomes and reduce costs for blood and plasma collectors, hospitals, and patients around the world. Its products and services help prevent a transfusion to a patient who does not need one and provide the right blood product, at the right time, in the right dose to the patient who does. It serves three markets: manufacturers of plasma derived pharmaceuticals, blood collectors, and hospitals. Its product categories include: Plasma, Blood Center, Hospital, and Software Solutions. Plasma includes plasma collection devices and consumables. Blood Center includes blood collection and processing devices and consumables. Hospital includes surgical blood salvage and blood demand diagnostic devices and consumables. Software Solutions includes information technology platforms and consulting services provided to all three markets. The products it manufactures and markets are subject to regulation by the Center of Biologics Evaluation and Research and the Center of Devices and Radiological Health of the United States Food and Drug Administration, and other non-United States regulatory bodies.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide